Navinta LLC has submitted an application to be registered as a bulk manufacturer of basic classes of controlled substances. No information is provided about the status of the application or any regulatory decision.
The Drug Enforcement Administration has issued a determination to modify the aggregate production quotas for the 2026 year for four Schedule II controlled substances—d,l‑amphetamine, d‑amphetamine (for sale),…
The U.S. Food and Drug Administration has instructed manufacturers of GLP‑1 weight‑loss medications to update their labeling to include a warning about a potential increased risk of a rare eye condition that could lead…
According to the FDA announcement, the agency concluded that LASIX (furosemide) oral solution, 10 mg/mL, was not removed from the market due to safety or effectiveness concerns. Consequently, the FDA will not initiate…
Congressional attention to kratom, a plant with opioid-like effects sold over the counter, is rising as some states consider bans and a senator has urged the administration to intervene. The extent of federal response…
The U.S. Food and Drug Administration has indicated it is evaluating approaches for designing early‑phase clinical trials of ibogaine drug products and has opened a docket for public comments. The Department of Health…
According to the supplied article, selling retatrutide commercially is prohibited by federal law, yet some companies have advertised the drug on social media platforms. The article notes that a "trusted seal" from…